[The anti-arrhythmia activity of amino acid-containing trimecaine derivatives on models of early occlusive and reperfusion arrhythmias in cats].
Experiments were conducted on models of early occlusion and reperfusion arrhythmias in cats to study the antiarrhythmic activity of trimecain, its morpholine analogue (MPT), and MPT derivatives containing glycine, magnesium salt of aspartic acid, and N-acetylglutaminic acid. All the compounds were injected in doses of 5% of LD50. A 22.5 mg/kg dose of trimecain prevented cardiac rhythm disorders after occlusion of the coronary arteries as well as after restoration of the coronary blood flow. Replacement of the diethyl group in the structure of trimecain by the morpholine ring led to diminution of antiarrhythmic activity, and MPT in a dose of 28.0 mg/kg, in distinction from the former, had no effect on the frequency of the occurrence of early occlusion arrhythmias and the duration of reperfusion arrhythmias. Introduction of amino acids as an anion into the MPT structure raised the antiarrhythmic activity of the last named.
Artem'eva
O V
OV
Department of Pharmacology, Mordovian State University, Saransk, Russia.
Napalkova
S M
SM
Kostin
Ia V
IaV
Skachilova
S Ia
SIa
D000596:Amino Acids / Q000627:therapeutic use*; D000818:Animals; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001145:Arrhythmias, Cardiac / Q000188:drug therapy* / Q000209:etiology; D002415:Cats; D016009:Chi-Square Distribution; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D017202:Myocardial Ischemia / Q000150:complications*; D015428:Myocardial Reperfusion Injury / Q000150:complications*; D013329:Structure-Activity Relationship; D013997:Time Factors; D014288:Trimecaine / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000596:Amino Acids; D000889:Anti-Arrhythmia Agents; D014288:Trimecaine